Behavioral Rehabilitation Market Growth and Outlook

The global behavioral rehabilitation market was valued at USD 154.67 billion in 2022 and is expected to exceed USD 221.33 billion by 2032, growing at a CAGR of 3.58% from 2023 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5026

Key Developments and Companies in the Behavioral Rehabilitation Market

• In May 2022, the Department of Health and Human Services (HHS) introduced a funding opportunity of nearly $15 million for a three-year federal grant to establish a program under the Substance Abuse and Mental Health Services Administration (SAMHSA). This initiative aims to enhance behavioral health care for nursing home and long-term care facility residents.
• In May 2020, Limbix secured approximately US$ 9 million in Series funding to develop digital treatments for young people suffering from depression.
• Behavioral Health Group (BHG) expanded its presence by acquiring Wellness Ambulatory Care in Knoxville, TN, in November 2020, thereby broadening its service offerings.
• In June 2021, Acadia Healthcare launched an innovative pilot program focused on reducing suicide risk among individuals receiving outpatient treatment for opioid use disorder.
• In March 2018, UC San Francisco partnered with the City of San Francisco and other public and private organizations to open a new facility addressing the city’s inpatient mental health needs. The center aims to double the number of beds available for patients who require non-acute care but are unable to live independently.

Key Players in the Behavioral Rehabilitation Market: In-Depth Company Overview

The behavioral rehabilitation market features several prominent players committed to advancing the treatment and management of behavioral health conditions. Here’s a closer look at these companies:

• Allergan, Inc.: A global pharmaceutical company, Allergan is renowned for its work in the mental health and neurology fields. It develops a wide range of treatments aimed at disorders such as depression, anxiety, and other psychiatric conditions. Allergan has an extensive portfolio that includes both branded and generic medications, and its innovative therapies focus on enhancing patient outcomes in behavioral health.
• Novartis AG: Headquartered in Switzerland, Novartis is a leading global healthcare company known for its commitment to improving mental health care. Novartis focuses on research and development of cutting-edge therapies for various psychiatric and neurological conditions. The company has an extensive pipeline that includes medications designed to treat mood disorders, anxiety, schizophrenia, and other behavioral health issues.
• Taro Pharmaceutical Industries: Taro Pharmaceutical, based in Israel, is a major player in the generic pharmaceutical sector, including psychiatric and neurological treatments. With a focus on producing high-quality, affordable medications, Taro plays a significant role in ensuring that behavioral health treatments are accessible to a wider patient population. Taro’s portfolio includes treatments for a variety of conditions, including anxiety and mood disorders.
• Perrigo Company plc: Perrigo, a global leader in consumer self-care, is involved in developing and manufacturing over-the-counter and prescription medicines. While the company is more widely known for its consumer health products, Perrigo also offers a range of treatments that address behavioral health concerns, including anxiety and depression. Perrigo’s focus is on making mental health solutions more affordable and accessible to the general population.
• Zynerba Pharmaceuticals: Specializing in cannabinoid-based therapies, Zynerba Pharmaceuticals focuses on the potential of cannabis-derived treatments for various behavioral health conditions, particularly in pediatric populations. Their flagship product, designed to treat youth suffering from depression, anxiety, and other disorders, represents the company’s commitment to exploring innovative treatment pathways in the behavioral rehabilitation market.
• Apotex Inc.: Apotex is a multinational pharmaceutical company headquartered in Canada, known for its broad portfolio of generic drugs, including treatments for psychiatric conditions. The company’s focus is on offering affordable and effective alternatives to branded medications, ensuring that patients with mental health issues have access to essential therapies.
• Sandoz AG: A division of Novartis, Sandoz is a global leader in generic pharmaceuticals, including medications for behavioral and mental health conditions. Sandoz works to provide cost-effective, high-quality therapies for a variety of psychiatric disorders. The company’s mission is to expand access to essential treatments, ensuring that people across the world can receive care for their mental health needs.
• Strides Arcolab Ltd.: Strides Arcolab is an India-based pharmaceutical company with a global presence. The company is involved in producing a wide range of medications, including those aimed at treating behavioral health conditions such as anxiety, depression, and other mental health disorders. Strides focuses on both generic drugs and novel therapies that offer alternative treatment options for patients in need of behavioral rehabilitation.
• TOLMAR Pharmaceuticals, Inc.: TOLMAR is a U.S.-based pharmaceutical company that specializes in the development and commercialization of therapeutic solutions, including those related to behavioral health. While the company has a diverse portfolio, it has been working to enhance the treatment options available for behavioral disorders through its innovative medications and focus on patient-centered care.
• Limbix: Limbix is a digital health company that focuses on developing technology-driven treatments for mental health conditions, particularly for young people. Limbix is at the forefront of integrating digital solutions with traditional therapeutic practices, with a strong emphasis on using virtual reality and digital therapeutics to treat youth suffering from depression, anxiety, and other behavioral health challenges. Their solutions aim to provide accessible and engaging treatment options, particularly for younger generations who are more familiar with digital platforms.

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/behavioral-rehabilitation-market

To own our research study instantly, Click here @  https://www.towardshealthcare.com/price/5026

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Healthcare Web Wire is a premier subsidiary of Towards Healthcare, dedicated to providing comprehensive insights and information related to the healthcare industry. With a commitment to delivering accurate and timely updates, Healthcare Web Wire serves as a vital resource for professionals, enthusiasts, and stakeholders within the healthcare sector. Our platform serves as a central hub for the latest news, trends and developments shaping the healthcare landscape. Join us on Healthcare Web Wire and become part of a vibrant community dedicated to advancing healthcare knowledge and shaping the future of healthcare worldwide.

Visit Dental Specifics: https://www.towardsdental.com

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare